Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Ovarian Neoplasms 3Recurrence 2Neoplasms 2Hypersensitivity 2Uterine Neoplasms 1Salivary Gland Neoplasms 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoadjuvant Therapy 1Lung Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Adenocarcinoma 1

Interventions

pembrolizumab 45Paclitaxel 8Cisplatin 8Carboplatin 8lenvatinib 7Pemetrexed 5Gemcitabine 4camrelizumab 3Docetaxel 3Capecitabine 3epacadostat 2avelumab 2Fluorouracil 2Cetuximab 2Acetaminophen 2vicriviroc 1sinoporphyrin sodium 1penpulimab 1olaparib 1etoposide phosphate 1enzalutamide 1balstilimab 1apatinib 1Temozolomide 1Tadalafil 1Standard of Care 1Serotonin 5-HT3 Receptor Antagonists 1Radiotherapy 1Radiosurgery 1Poly(ADP-ribose) Polymerase Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Parkinson Disease 4, Autosomal Dominant Lewy Body × Poly(ADP-ribose) Polymerase Inhibitors × Clear all
NCT05392686 2022-05-26

PD1 and PARP for Maintenance Therapy in NSLLC

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
52 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡